Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

View Latest Updates Visitor Restrictions Visitor Restrictions
Explore URMC
menu

Brea C. Lipe, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 276-2596

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Locations

Wilmot Cancer Institute Oncology
601 Elmwood Ave
Rochester, NY 14642-0001

Oncology: (585) 275-5823

Faculty Appointments

Patient Care Setting

Cancer

Biography

I am the clinical director of Wilmot's multiple myeloma program, and in the laboratory and in the clinic, I am focused on improving the care of patients with multiple myeloma and other plasma cell dyscrasias. Treatment options and our understanding of multiple myeloma have changed dramatically in the last 10 years. The rapid pace of change, intrinsic disease complexity, and the ability to impact patient lives still leaves me amazed and humbled every day.

I believe that it's important to know my patients as individuals to understand the situational circumstance and personality that drives their treatment goals. Multiple myeloma is a lifelong journey and a strong partnership with my patients is essential to achieving the best quality of care. I have a strong interest in clinical research and like to offer my patients a variety of clinical trial options and treatments based on the most recent data. I have a dedicated support team, so that we can offer patients a team with real myeloma-specific expertise.

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Outside of work, I love to grow things -- flowers, vegetables, orchids, animals, children. I have gotten some of my best gardening tips from my patients.

Conditions I treat:

- Multiple myeloma
- Other plasma cell disorders

Research

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Credentials

Specialties

  • Hematology - American Board of Internal Medicine
  • Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2005
MD | Albany Medical Center

Post-doctoral Training & Residency

07/01/2008 - 06/30/2011
Fellowship in Hematology/Oncology at Dartmouth-Hitchcock Medical Center

07/01/2006 - 06/30/2008
Residency in Internal Medicine at Dartmouth-Hitchcock Medical Center

07/01/2005 - 06/30/2006
Internship in Internal Medicine at Dartmouth-Hitchcock Medical Center

VIEW ALL expand_more

Awards

2017 - Present
Leadership Academy
Sponsor: Southwest Oncology Group (SWOG)

2011
Department of Internal Medicine OSARM Faculty Incubator Scholar

2011
Clinical Research Training Institute Clinical Scholar for ASH

2009
Award for Excellence in Teaching

2007
Award for Excellence in Teaching

2001 - 2005
Frank C. Knievel Scholarship Award

1996 - 2001
First Generation Diversity Scholarship

VIEW ALL expand_more

Clinical Trials

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Lead Researcher: Brea C Lipe

This is a multicenter, multi-country study consisting of two parts: Part 1) Evaluation of dosing amounts of CC-220 alone, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ, and CC-220 in combination with DEX and CFZ; Part 2) Expansion of the highest tolerated doses of CC-220 alone, CC-220 in combination with DEX (DoubleT) for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

View Study Details

A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma

Lead Researcher: Brea C Lipe

This trial will study SEA-BCMA, a monoclonal antibody, to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SEA-BCMA should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.

View Study Details

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Lead Researcher: Brea C Lipe

Patients will be treated with Daratumumab and Lenalidomide or Lenalidomide alone for two years and then tested for minimal residual disease. Minimal residual disease is the evidence for the presence of residual malignant cells, even when so few cancer cells are present that they cannot be found by routine means. In a patient who has been treated, the detection of MRD indicates that treatment is incomplete. MRD can thus distinguish who needs intensive and potentially more toxic therapy from those who do not. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be either continue or discontinue the assigned treatment. Patients are treated for up to 7 years and followed for up to 15 years.

View Study Details

IMMY17015: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies

Lead Researcher: Brea C Lipe

This research is being done to help us determine if the study drug is safe and can be tolerated for the treatment of multiple myeloma or certain lymphomas.

View Study Details

ULAB-16115 A program for following disease progression in Multiple Myeloma

Lead Researcher: Brea C Lipe

The purpose of this study is to collect clinical data along with bone marrow aspirate samples to see if there is a way to determine which patients are more or less likely to experience disease progression. This study will involve identifying different markers on the surfaces of the plasma cells and will look at protein expression. We will then correlate those findings with data from your medical records over time. If you decide to take part in this study, you will be asked to allow additional bone marrow aspirate and blood samples to be collected for research at several time points. These additional samples will be collected during routine testing time points as required for your routine care. We will also collect information about your disease and treatment from your medical record.

View Study Details

IMMY-16088 A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma),IMMY-16088 A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma)

Lead Researcher: Brea C Lipe

This is an open-label study, which means that both you and your study doctor will know how much selinexor and the names of other medications you are taking. You, and all other patients in this study, will take the study drug selinexor, plus dexamethasone and either pomalidomide, bortezomib, lenalidomide, or daratumumab. The treatment period consists of blocks of time called cycles. The number of treatment cycles you receive will depend on how well you are doing on the treatment and how well your cancer responds to it. This study includes four different treatment combinations: • Selinexor, dexamethasone and pomalidomide (abbreviated as SPd) • Selinexor, dexamethasone and bortezomib (abbreviated as SVd) • Selinexor, dexamethasone and lenalidomide (abbreviated as SRd) • Selinexor, dexamethasone, daratumumab (abbreviated SDd)

View Study Details

UMMY17073: A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency

Lead Researcher: Brea C Lipe

If you decide to participate in this study you will receive denosumab every 4 weeks for a total of 12 cycles.

View Study Details

A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Lead Researcher: Brea C Lipe

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.

View Study Details

Publications

Journal Articles

4/9/2019
Li D, Chiu G, Lipe B, Hopkins RA, Lillis J, Ashton JM, Paul S, Aljitawi OS. "Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture." Blood advances.. 2019 Apr 9; 3(7):1011-1026.

4/1/2019
Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T. "Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 Apr 1; :JCO1802096. Epub 2019 Apr 01.

1/2019
Hsu CM, Bennett JM, Lipe B. "Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma." Clinical lymphoma, myeloma & leukemia.. 2019 Jan 0; 19(1):e29-e32. Epub 2018 Sep 05.

VIEW ALL PUBLICATIONS